Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Michael Parini
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:developsTreatmentFor |
gptkb:Fabry_disease
gptkb:hemophilia_B gptkb:Gaucher_disease |
| gptkbp:focusesOn |
gene therapy
|
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Chris_Hollowood
|
| gptkbp:headquartersLocation |
gptkb:Stevenage,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Freeline Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:parentCompany |
gptkb:Syncona
|
| gptkbp:platform |
AAV gene therapy
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
FRLN
|
| gptkbp:website |
https://www.freelinetx.com/
|
| gptkbp:bfsParent |
gptkb:Syncona
|
| gptkbp:bfsLayer |
7
|